1 – 10 of 38
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Genetically adjusted PSA levels for prostate cancer screening
(
- Contribution to journal › Article
-
Mark
Genome-wide association study of prostate-specific antigen levels in 392,522 men identifies new loci and improves cross-ancestry prediction
2023)(
- Working paper/Preprint › Preprint in preprint archive
-
Mark
A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry
(
- Contribution to journal › Article
- 2021
-
Mark
Mendelian randomisation study of smoking exposure in relation to breast cancer risk
(
- Contribution to journal › Article
-
Mark
Combined associations of a polygenic risk score and classical risk factors with breast cancer risk
(
- Contribution to journal › Article
-
Mark
Breast cancer risk factors and survival by tumor subtype : pooled analyses from the Breast Cancer Association Consortium
2021) In Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 30(4). p.623-642(
- Contribution to journal › Article
-
Mark
Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment
(
- Contribution to journal › Article
- 2018
-
Mark
A comprehensive analysis of polymorphic variants in steroid hormone and insulin-like growth factor-1 metabolism and risk of in situ breast cancer : Results from the Breast and Prostate Cancer Cohort Consortium
(
- Contribution to journal › Article
- 2017
-
Mark
Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer
(
- Contribution to journal › Article
- 2016
-
Mark
Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations
(
- Contribution to journal › Article